Harms of Treatment; Height and Longevity: It's PodMed Double T! (with audio)
(MedPage Today) -- This week ' s topics also include when to start a common Parkinson ' s disease drug and dapagliflozin ' s effects on heart risks (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - January 26, 2019 Category: Cardiology Source Type: news
Effect of Dapagliflozin in T2D Patients With Stages 3b-4 CKD Effect of Dapagliflozin in T2D Patients With Stages 3b-4 CKD
Is dapagliflozin an effective therapeutic option for patients with type 2 diabetes and chronic kidney disease? How does it impact clinical outcomes in these patients?Nephrology Dialysis Transplantation (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 22, 2018 Category: Consumer Health News Tags: Nephrology Journal Article Source Type: news
AHA: Dapagliflozin Noninferior to Placebo for MACE in T2DM
TUESDAY, Nov. 13, 2018 -- Treatment with dapagliflozin is noninferior to placebo for major adverse cardiovascular events (MACE) among patients with type 2 diabetes with or at risk for atherosclerotic cardiovascular disease, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 13, 2018 Category: Pharmaceuticals Source Type: news
AHA: Mixed Results with Dapagliflozin in T2D Patients
(MedPage Today) -- SGLT2 inhibitor didn ' t change MACE rate, but did result in other positive CV outcomes (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - November 10, 2018 Category: Cardiology Source Type: news
DECLARE-TIMI 58: Dapagliflozin Cuts Heart Failure in Diabetes DECLARE-TIMI 58: Dapagliflozin Cuts Heart Failure in Diabetes
The trial did not show a significant reduction in major adverse cardiovascular events but does extend the heart failure benefits of SGLT2 inhibitors to the primary prevention population.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 10, 2018 Category: Consumer Health News Tags: Cardiology News Source Type: news
Diabetes Drug, Farxiga, Might Also Ease Heart Failure Risks
SATURDAY, Nov. 10, 2018 -- The diabetes drug Farxiga might do double-duty for patients, helping to ward off another killer, heart failure, new research shows.
Type 2 diabetics who took Farxiga (dapagliflozin) saw their odds of hospitalization for... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - November 10, 2018 Category: General Medicine Source Type: news
Diabetes Drug Farxiga (dapagliflozin) Might Also Ease Heart Failure Risks
SATURDAY, Nov. 10, 2018 -- The diabetes drug Farxiga might do double-duty for patients, helping to ward off another killer, heart failure, new research shows.
Type 2 diabetics who took Farxiga (dapagliflozin) saw their odds of hospitalization for... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - November 10, 2018 Category: General Medicine Source Type: news
Diabetes Drug Might Also Ease Heart Failure Risks
SATURDAY, Nov. 10, 2018 -- The diabetes drug Farxiga might do double-duty for patients, helping to ward off another killer, heart failure, new research shows.
Type 2 diabetics who took Farxiga (dapagliflozin) saw their odds of hospitalization for... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - November 10, 2018 Category: General Medicine Source Type: news
Dapagliflozin CV Outcomes; New Guideline on Congenital Adrenal Hyperplasia
(MedPage Today) -- News and commentary from the endocrinology world (Source: MedPage Today Pediatrics)
Source: MedPage Today Pediatrics - September 28, 2018 Category: Pediatrics Source Type: news
DECLARE-TIMI 58: HF Benefit for Dapagliflozin in Diabetes? DECLARE-TIMI 58: HF Benefit for Dapagliflozin in Diabetes?
Top-line data from DECLARE-TIMI 58 hint that CV benefit of the SGLT2 inhibitor dapagliflozin for type 2 diabetes is driven by improvement in heart failure, but 60% of patients were primary prevention.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 25, 2018 Category: Consumer Health News Tags: Cardiology News Source Type: news
How One Class Of Diabetes Medications May Lead To Flesh-Eating Genital Infections
If you are taking canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, or any other sodium-glucose cotransporter-2 (SGLT2) inhibitor, you may want to pay attention to this FDA warning. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - September 1, 2018 Category: Pharmaceuticals Authors: Bruce Y. Lee, Contributor Source Type: news
Incretin/SGLT-2 Combo Efficacy Persists 2 Years
(MedPage Today) -- Exenatide plus dapagliflozin maintained biomarker benefits in long-term study (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - June 26, 2018 Category: Cardiology Source Type: news
Dapagliflozin Tied to Drop in Hepcidin Levels
(MedPage Today) -- Decrease may boost hematocrit and hemoglobin after SGLT-2 inhibitor therapy (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - May 20, 2018 Category: Urology & Nephrology Source Type: news
Real-World Study Shows INVOKANA ® (canagliflozin) 300mg Demonstrates Better Blood Glucose Control Than Farxiga® (dapagliflozin) 10mg in Patients with Type 2 Diabetes
(Source: Johnson and Johnson)
Source: Johnson and Johnson - April 27, 2018 Category: Pharmaceuticals Source Type: news
New data from landmark CVD-REAL study of patients with type-2 diabetes confirms CV benefits associated with SGLT-2 Inhibitors
AstraZeneca has announced results from a new analysis of its landmark CVD-REAL study, the first large real-world evidence study of its kind evaluating the risk of all-cause death (ACD), hospitalisation for heart failure (hHF), heart attack (myocardial infarction or MI) and stroke in patients with type-2 diabetes (T2D) receiving treatment with SGLT-2 inhibitors (SGLT-2i), including Farxiga (dapagliflozin) versus other glucose-lowering medicines. (Source: World Pharma News)
Source: World Pharma News - March 14, 2018 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news
